

Project Evaluation, Selection and Additional Funding

BioCurate runs two cycles of new project submissions and evaluations per year. A preliminary evaluation of a project follows submission of a **BioCurate Opportunity Assessment (BOA)** application at the beginning of March and September each year, with outcomes announced at the end of the month.

If selected, applicants are requested to further submit a more detailed **Expression of Interest (EOI)** application within one month of the announcement. All BOA and EOI applications must be submitted via Monash Innovation or University of Melbourne Business Development and Innovation.



Important Dates for 2021

BOA Submissions due:
1 September

BOA and PoC Fund Outcomes:
30 September

EOI Submissions due:
1 November

EOI Outcomes:
1 December

EOI applicants are encouraged to present their project to BioCurate early in the EOI review process, which runs for one month following submission.

Criteria for success

A project must:

- Address an unmet clinical need Unmet medical need -
Industry perspective
- Be clearly differentiated (preferably on efficacy) from other approaches on the market or in clinical development
- Have Commercial potential and clear potential for licensing Valuation of your early
drug candidate
- Have a Clinical & Regulatory path that can be defined & executed
- Target must have verified link to human disease Target validation
- Be supported by robust, reproducible scientific data & validated reagents & assays
- Have no IP “showstoppers” IP protection and
patenting strategy
 - Existing IP not necessary, but must have clear IP potential
 - No known freedom-to-operate issues

Follow the links or go to the BioCurate website biocurate.com for fact sheets regarding the criteria for success


Indication

All disease areas will be considered

Modality

In Scope - small molecule, antibody or other biological, peptides, cell therapy, gene therapy, drug/device/diagnostic combinations


Out of Scope - diagnostics (unless companion), devices, veterinary medicines, vaccines



Applications that do not progress to a request to submit an EOI may be asked to develop a Proof of Concept (PoC) Fund experimental plan.

Proof of Concept Fund

1. BioCurate has developed a PoC fund to support projects that require additional experimental validation following BOA or EOI review, where the identified scientific gaps are a barrier to project progression at BioCurate
2. Eligible projects must have met most of the **Criteria for Success**
3. Upon notification, applicants for PoC funding have 30 days to submit an experimental plan with a budget ca. \$100k to address the experimental gaps.
4. Where available, internal leveraged funds can be used to top up the BioCurate PoC funds
5. Projects can receive > 1 rounds of PoC funding
6. Applications may not proceed to further evaluation should the PoC data not support progression
7. Upon review of the PoC final report the project may proceed to an EOI application or straight to Exclusive Evaluation and License Agreements and then enter the BioCurate Portfolio
8. The University will retain ownership of the IP rights in the Technology and will own any improvements to its Background IP and IP arising from the performance of the PoC Project



For more information, contact Dr Andy Allen: a.allen@biocurate.com